

1 **The Construction and Analysis of ceRNA Network and Immune** 2 **Infiltration in Kidney Renal Clear Cell Carcinoma**

3

4 Lugang Deng ¹, Zhi Qu ², Peixi Wang ², Nan Liu ^{1, 2, 3, *} 

5

6 ¹ School of Public Health, Guangzhou Medical University, Guangzhou, 511436, P. R.
7 China

8 ² Institute of Chronic Disease Risks Assessment, School of Nursing and Health,
9 Henan University, Kaifeng, 475004, P. R. China

10 ³ Pinghu Hospital, Health Science Center, Shenzhen University, Shenzhen, 518116, P.
11 R. China.

12

13 *Corresponding author:

14 **Nan Liu**

15 13688869875@163.com

16 ORCID: orcid.org/0000-0002-8895-3169

17

18

19

20

21

22

23 Abstract

24 **Background:** Kidney renal clear cell carcinoma (KIRC) has the highest invasion,
25 mortality and metastasis of the renal cell carcinomas and seriously affects patients'
26 quality of life. However, the composition of the immune microenvironment and
27 regulatory mechanisms at transcriptomic level such as ceRNA of KIRC are still
28 unclear.

29 **Methods:** We constructed a ceRNA network associated with KIRC by analyzing the
30 long noncoding RNA (lncRNA), miRNA and mRNA expression data of 506 tumor
31 tissue samples and 71 normal adjacent tissue samples downloaded from the Cancer
32 Genome Atlas (TCGA) database. In addition, we estimated the proportion of 22
33 immune cell types in these samples through "The Cell Type Identification by
34 Estimating Relative Subsets of RNA Transcripts". Based on the ceRNA network and
35 immune cells screened by univariate Cox analysis and Lasso regression, two
36 nomograms were constructed to predict the prognosis of patients with KIRC. Receiver
37 operating characteristic curves (ROC) and calibration curves were employed to assess
38 the discrimination and accuracy of the nomograms. Consequently, co-expression
39 analysis was carried out to explore the relationship between each prognostic gene in a
40 Cox proportional hazards regression model of ceRNA and each survival-related
41 immune cell in a Cox proportional hazards regression model of immune cell types to
42 reveal the potential regulatory mechanism.

43 **Results:** We established a ceRNA network consisting of 12 lncRNAs, 25 miRNAs
44 and 136 mRNAs. Two nomograms containing seven prognostic genes and two
45 immune cells, respectively, were successfully constructed. Both ROC [Area Under
46 Curves (AUCs) of 1, 3 and 5-year survival in the nomogram based on ceRNA
47 network: 0.779, 0.747 and 0.772; AUCs of 1, 3 and 5-year survivals in nomogram

48 based on immune cells: 0.603, 0.642 and 0.607] and calibration curves indicated good
 49 accuracy and clinical application value of both models. Through co-correlation
 50 analysis between ceRNA and immune cells, we found both LINC00894 and
 51 KIAA1324 were positively correlated with follicular helper T (Tfh) cells and
 52 negatively correlated with resting mast cells.

53 **Conclusions:** Based on the ceRNA network and tumor-infiltrating immune cells, we
 54 constructed two nomograms to predict the survival of KIRC patients and
 55 demonstrated their value in improving the personalized management of KIRC.

56

57 **Keywords:** Kidney renal clear cell carcinoma; TCGA; Competing endogenous RNA
 58 network; Immune cell; Prognosis

59

60 **Introduction**

61 Renal cell carcinoma is a malignant kidney tumor that the American Cancer Society
62 reports was diagnosed in 65,340 patients, and caused 14,970 deaths, in the United
63 States during 2018 (1). It is a serious health problem worldwide, and the economic
64 burden of the disease has steadily increased during the last century (2). Kidney renal
65 clear cell carcinoma (KIRC) is the subtype of renal cell carcinoma with the highest
66 invasiveness, mortality and metastasis rates (3); it is typically screened and diagnosed
67 through computed tomography (CT), magnetic resonance imaging (MRI) and
68 pathological section testing in the clinic (4). Several difficulties continue to make
69 KIRC a challenge to treat, including its stealth in early stages, a lack of effective
70 biomarkers, radiation risks and the high cost of diagnostic imaging required.
71 Underlying biomarkers and molecular mechanisms for the prevention, diagnosis and
72 prognosis of KIRC require further studies.

73 Long noncoding RNAs (lncRNAs) contain more than 200 nucleotides without the
74 function of encoding proteins and have achieved attention recently because of their
75 potential for exploring novel biomarkers in diseases and for elucidating mechanisms
76 of biological processes (5, 6). Current research reveals that lncRNA plays an
77 important role in the genesis and development of tumors through interactions with
78 competing endogenous RNA (ceRNA) or by acting as microRNA sponges (7).
79 Tumor-infiltrating immune cells are a major component of the tumor
80 microenvironment and affect the clinical outcomes and pathological staging of
81 multiple tumor types (8, 9). Some studies suggest lncRNA can affect tumor
82 development and tumor immune cell microenvironment through the ceRNA network
83 (10-12). Therefore, exploring interactions between the ceRNA network and various
84 immune cells in the development of KIRC is essential.

85 In this study, we construct a ceRNA network related to the occurrence and
86 development of KIRC using transcriptome and clinical data from the Cancer Genome
87 Atlas (TCGA) to explore potential molecular mechanisms. In addition, we used “The
88 Cell Type Identification by Estimating Relative Subsets of RNA Transcripts algorithm”
89 (CIBERSORT) algorithm to assess differences in the composition of immune cells
90 within tumor tissues and normal tissues. Furthermore, predictive nomograms were
91 constructed based on the ceRNA network and on significant immune cells. Finally, we
92 evaluated the relationship between tumor-infiltrating immune cells and the ceRNA
93 network to identify the underlying regulatory mechanisms.

94

95 **Materials and methods**

96 *Data source and selection*

97 A flowchart illustrating the research process of our study is provided in Figure 1. Data
98 on lncRNA, miRNA and mRNA expression of KIRC patients were downloaded from
99 the Cancer Genome Atlas (TCGA) database (<https://portal.gdc.cancer.gov/>) through
100 the GDC data transfer tool. Relevant clinical information including age, gender,
101 survival data (vital status, days to death and days to last follow-up), grade and TNM
102 stage of tumor tissues was also obtained for further analysis. We excluded samples
103 with incomplete survival or pathological staging data, as well as duplicate samples.
104 Only samples with both mRNA and miRNA expression profiles were included in this
105 study. Correspondingly, the adjacent and paired normal tissues collected from the
106 included patients was set as the control group.

107

Figure 1

108 *Differential expression analysis*

109 Based on the HTSeq-Counts data of included samples, we used the “DESeq2”

110 package (13) (<http://bioconductor.org/packages/DESeq2/>) of Bioconductor to screen
111 for differentially expressed lncRNAs (DElncRNAs), miRNAs (DEmiRNAs) and
112 mRNAs (DEmRNAs) between KIRC tissue and normal adjacent tissue. The log fold
113 change (FC) criterion for differential expression was set as $|\log_2(FC)| > 1$ and the false
114 discovery rate (FDR) at < 0.05 . For the differential expression results of each type of
115 RNA, volcano plots and heatmaps were generated through R packages “ggpolt2” and
116 “pheatmap.”

117 ***Construction of lncRNA-miRNA-mRNA ceRNA network and survival analysis***

118 Using the differential expression results, we predicted the miRNAs-lncRNAs
119 interactions and the miRNAs-mRNAs interactions based on the starBase v2.0
120 database (14, 15) (<http://starbase.sysu.edu.cn/starbase2/index.php>), which contained
121 the miRNA-target interactions overlapped with CLIP-Seq data. We conducted
122 hypergeometric tests and correlation analysis to filter the predicted interactions with
123 $FDR < 0.05$ as the screening criteria. In addition, the lncRNA-miRNA-mRNA
124 regulatory network of KIRC was visualized using Cytoscape v.3.8.1
125 (<http://cytoscape.org/>) (16). Besides, we conducted a Kaplan-Meier (K-M) survival
126 curve analysis to assess the prognostic value of genes in the KIRC ceRNA network.

127 ***ceRNA network: Cox proportional hazards regression model***

128 Firstly, significant variables were screened for integration into the initial Cox model
129 using univariate Cox analysis. Next, a least absolute shrinkage and selection operator
130 (Lasso) regression was employed to further evaluate the fitness of multifaceted
131 models and filter variables. Finally, we generated a nomogram of from multivariate
132 Cox proportional hazards regression models to predict the prognosis of KIRC patients.
133 To confirm the discrimination and precision of the nomogram, receiver operating
134 characteristic curves (ROC) and calibration curves were employed. In addition, we

135 calculated the risk score of each patient and then divided patients into high and low
136 risk groups based on the median to conduct a K-M survival curve analysis.

137 ***Tumor-infiltrating immune cells: CIBERSORT estimation and survival analysis***

138 To analyze differences between the two groups at the level of immune cells, and
139 explore the connection between key biomarkers in the ceRNA network and immune
140 cells, we estimated the proportion of 22 kinds of immune cell types in 506 tumor
141 tissues and 71 normal adjacent tissues by CIBERSORT (17)
142 (<http://cibersort.stanford.edu/>), an algorithm for characterizing cell composition of
143 complex tissues from their gene expression profiles. Only samples with CIBERSORT
144 output of $P < 0.05$ were included in further analysis. After screening samples, we
145 searched for immune cells with significant differences between cancer tissues and
146 normal adjacent tissues, as indicated by a Wilcoxon rank-sum test. A K-M survival
147 curve analysis was performed to evaluate the relationship between the content of
148 different immune cells and the overall survival of KIRC patients.

149 ***Tumor-infiltrating immune cells: Cox proportional hazards regression model***

150 Immune cells with significant effects in univariate Cox analysis were integrated into
151 the initial Cox model and the Lasso regression again used to evaluate the fitness of
152 multifaceted models and filter variables further. As above, we constructed a
153 nomogram based on the multivariate model of immune cells, and used ROC and
154 calibration curves to confirm the discrimination and precision of the nomogram.
155 Similarly, we conducted a K-M survival curve analysis by dividing patients into high
156 and low risk groups according to the median of risk score. Finally, a Pearson
157 correlation analysis was used to explore the relationship between genes and immune
158 cells.

159 **Statistical Analysis**

160 Only two-sided P -values < 0.05 was considered statistically significant. All statistical
161 analyses were conducted in R version 4.0.2 software (Institute for Statistics and
162 Mathematics, Vienna, Austria; www.r-project.org) (packages: corplot, DESeq2,
163 GDCRNATools, ggplot2, glmnet, pheatmap, rms, survival, survminer, timeROC).

164 165 **Results**

166 ***Differential expression in lncRNAs, miRNAs and mRNAs***

167 After screening the samples of TCGA-KIRC, we constructed an experimental group
168 and a control group containing of 506 tumor tissues and 71 normal adjacent tissues,
169 respectively. Compared to the control group, we identified 357 DElncRNAs (287
170 up-regulated and 70 down-regulated), 132 DEmiRNAs (61 up-regulated and 71
171 down-regulated) and 3092 DEMRNAs (2032 up-regulated and 1060 down-regulated)
172 using the cutoffs of the $|\log_2(FC)| > 1$ and $FDR < 0.05$ (Figure 2a-g).

173 **Figure 2**

174 **Figure 3**

175 **Table 1**

176 ***Construction of lncRNA-miRNA-mRNA ceRNA network and survival analysis***

177 Using the starBase v2.0 database and ceRNA theory, a lncRNA-miRNA-mRNA
178 ceRNA network consisting of 173 genes (12 lncRNAs, 25 miRNAs and 136 mRNAs)
179 was established (Figure 3a and Table 1). A K-M survival curve analysis to assess the
180 prognostic value of nodes in the ceRNA network revealed 83 genes (10 lncRNAs, 7
181 miRNAs and 66 mRNAs) related to the overall survival of KIRC patients. Survival
182 curves of the top three (according to P -value) lncRNAs (PVT1, AC005154.1,
183 AC015813.1), miRNAs (hsa-miR-21-5p, hsa-miR-130b-3p, hsa-miR-204-5p), and
184 mRNAs (MXD3, VPS13D, KCNN4) are shown in Figures 3b-d, e-g and h-j,

185 respectively.

186 ***ceRNA network: Cox proportional hazards regression model***

187 Univariate Cox analysis applied to filter genes in the ceRNA network retained 97
188 genes for incorporation into the initial model (Table S1). Lasso regression analysis
189 indicated that 15 genes were statistically significant in this model. Subsequently, a
190 Cox proportional hazards regression model with seven genes was established through
191 further screening of key genes based on the Akaike Information Criterion (AIC).
192 Finally, we constructed a nomogram to predict the 1, 3 and 5-year overall survival
193 probability of KIRC patients. ROC [Area Under Curves (AUCs)] for the model gave
194 1, 3 and 5-year survivals of 0.779, 0.747 and 0.772, respectively, which reflected the
195 discrimination and precision of the nomogram with calibration curves (Figure 4).
196 Overall survival (based on K-M curves) of the high-risk group is lower than that of
197 the low-risk group (Figure S1). Survival curves of the genes in the model are also
198 provided in Figure S1.

199 **Figure 4**

200 ***Tumor-infiltrating immune cells: CIBERSORT estimation and survival analysis***

201 The analysis by CIBERSORT identified five normal tissue samples and 206 tumor
202 tissue samples for inclusion in subsequent analysis ($P < 0.05$) and the proportions of
203 22 immune cells in each sample are displayed in the histogram and heat map of
204 Figure 5. A Wilcoxon rank-sum test showed that naive B cells ($P < 0.001$), plasma
205 cells ($P < 0.001$), CD8 T cells ($P = 0.014$), CD4 naive T cells ($P < 0.001$), CD4
206 memory resting T cells ($P = 0.013$), regulatory (Tregs) T cells ($P = 0.015$), gamma
207 delta T cells ($P = 0.021$), resting dendritic cells ($P = 0.016$) and resting mast cells ($P =$
208 0.048) all varied between the two tissue sample types (Figure 5c). Based on the results
209 of K-M survival curve analysis, five immune cells, including memory B cells, plasma

cells, follicular helper T (Tfh) cells, T regulatory (Tregs) cells and resting mast cells were related to overall survival of KIRC patients (Figure S2). The clinical correlation of 22 immune cells is displayed in Figure S3.

Figure 5

Tumor-infiltrating immune cells: Cox proportional hazards regression model

After filtering based on univariate Cox analyses (Table S2), two of 22 immune cells (Tfh and resting mast cells) were incorporated into the initial regression model. Lasso regression analysis and AIC were then employed for further optimization of the model, and both cells were kept in the final Cox proportional hazards regression model. A nomogram was developed to predict the 1, 3 and 5-year overall survival probability of KIRC patients based on the model. Both the ROC (AUCs of 1, 3 and 5-year survivals: 0.603, 0.642 and 0.607) and the calibration curves suggested that the nomogram had good accuracy (Figure 6). The K-M survival curves suggested that significant differences existed in the overall survival of the high versus low-risk group (Figure S4).

Figure 6

Co-expression analysis of key genes and immune cells

Pearson correlation analysis was used to explore the co-expression pattern between 22 types of immune cells (Figure 7a). Similarly, the co-expression relationship between the key biomarkers and immune cells of the two models is illustrated in Figure 7b. Tfh cells are positively correlated with LINC00894 (Figure 7c, $R = 0.36$, $P < 0.001$) and KIAA1324 (Figure 7d, $R = 0.39$, $P < 0.001$), while resting mast cells are negatively correlated with LINC00894 (Figure 7e, $R = -0.32$, $P < 0.001$) and KIAA1324 (Figure 7f, $R = -0.30$, $P < 0.001$).

Figure 7

235 ***Validation of the correlation between key genes and immune cells***

236 Multiple databases were searched to verify the correlation between the key genes
237 (LINC00894 and KIAA1324) and immune cells (Tfh cells and resting mast cells)
238 identified. B cell lymphoma 6 (BCL6), CXCL13, CD10 (MME), ICOS and PD-1
239 (PDCD1) were the most common surface markers of Tfh cells in the CellMarker
240 database (Figure S5). In the Oncomine™ platform, we explored the expression of
241 KIAA1324 and Tfh markers among various cancers. KIAA1324, BCL6, CXCL13,
242 ICOS and PDCD1 were highly expressed and MME was downregulated in KIRC
243 compared to normal kidney tissue (Figure S6); median rank and *P*-values are listed in
244 Table S3.

245 Using the Gene Expression Profiling Interactive Analysis (GEPIA), KIAA1324 is
246 positively correlated with CXCL13, ICOS and PDCD1 in KIRC (Figure S7), and
247 LINC00894 is positively correlated with BCL6, ICOS and PDCD1 in KIRC (Figure
248 S8). Similarly, the results of the LinkedOmics database showed that KIAA1324 was
249 positively correlated with BCL6, CXCL13, ICOS and PDCD1 in KIRC. In addition,
250 the expression of KIAA1324 was significantly different among tumor stages and
251 related to tumor purity in KIRC (Figure S9).

252

253 **Discussion**

254 KIRC is one of the most common and malignant subtypes of kidney tumors (3).
255 However, because of limitations in early detection and a lack of sensitive biomarkers,
256 patients with KIRC typically have a poor prognosis. Recently, ceRNA was identified
257 as playing a potentially important role in the molecular regulatory function of
258 tumorigenesis and growth, and in affecting differences in immune-infiltrating cells
259 within multiple tumors. In this study, we investigated the role and connection of the

260 ceRNA network and immune infiltration in KIRC to explore key prognostic
261 biomarkers and potential regulatory mechanisms.

262 We established a ceRNA network consisting of 12 lncRNAs, 25 miRNAs and 136
263 mRNAs and compared the composition differences of immune cells related to KIRC.
264 Based on the results, two prediction nomograms consisting of seven genes and two
265 immune cells, respectively, were constructed to evaluate overall survival. A
266 correlation analysis of the key factors in both nomograms indicated that both
267 LINC00894 (lncRNA) and KIAA1324 (protein-coding RNA) were positively
268 correlated with Tfh cells and negatively correlated with resting mast cells.
269 Consequently, we infer that ceRNA regulatory function, in which both LINC00894
270 and KIAA1324 participate, and Tfh cells and resting mast cells may play a crucial
271 role in the development and treatment of KIRC.

272 LINC00894 is lncRNA derived from a locus on the X chromosome that is
273 differentially expressed in various cancers (18). Similar to our work, Liang (19)
274 reported that LINC00894 was a tumor-special lncRNA in KIRC that was upregulated
275 in tumor tissues and correlated with overall survival time. Epithelial-to-mesenchymal
276 transition (EMT) regulating miRNAs regulate drug resistance and cancer progression
277 and metastasis (20, 21). LINC00894 can inhibit the TGF- β 2/ZEB1 signaling pathway
278 by acting as the sponge of EMT-regulating miR-200, or can be upregulated by ER α
279 activation and positively regulate the expression of miR-200a-3p and miR-200b-3p,
280 which results in induction of the TGF- β 2/ZEB1 signaling pathway to reduce the
281 occurrence of drug resistance in breast cancers (18, 22, 23). In our study, LINC00894
282 might suppress the expression of hsa-miR-342-3p, which has an important role in
283 progression, staging and metastasis of various cancers (24-27). In view of the
284 upregulation of hsa-miR-342-3p contributing to gefitinib resistance via targeting

285 CPA4 in non-small cell lung cancer (28), we speculate that LINC00894 is involved in
286 the progression of cancer and may be a promising treatment target to eliminate drug
287 resistance in patients with KIRC.

288 KIAA1324, also known as EIG121, encodes a 1013 amino acid transmembrane
289 protein that shows high sequence conservation among different species. In type I
290 endometrial cancer (estrogen-related), the expression of KIAA1324 is upregulated,
291 but it is downregulated in type II endometrial cancer (not estrogen-related), which is
292 more malignant than type I (29). KIAA1324 may be a novel suppressor, being
293 epigenetically downregulated in gastric cancer (30); in addition, its high expression in
294 endometrial and pancreatic carcinoma predicts improved survival (31, 32). However,
295 increased expression of KIAA1324 in ovarian cancer is associated with a poor
296 prognosis (33). These studies indicate that KIAA1324 may exhibit different biological
297 functions in various cancers. Furthermore, recent mechanistic studies reveal that
298 KIAA1324 is localized to endosome-lysosome compartments and associated with
299 autophagy, which helps protect cells from cell death by upregulating the autophagy
300 pathway under unfavorable conditions, such as starvation or chemotherapy (34).
301 Therefore, we infer that overexpressed KIAA1324 helps cancer cells proliferate and
302 resist chemotherapy in KIRC.

303 In this study, we explored five among 22 types of immune cells related to patient
304 prognosis, and screened out the Tfh cells and resting mast cells to construct a Cox
305 proportional hazards regression model, which evaluation of its AUC suggests has
306 clear clinical value. Gou et al. (35) also explored the relationship between immune
307 cells and renal cell carcinoma, and similar to our research, found Tfh cells were
308 associated with poor prognosis and resting mast cells were positively associated with
309 long term survival.

310 Under the action of myeloid professional antigen presenting cells (APC), naive
 311 CD4⁺ T cells could differentiate into Tfh cells and non-Tfh effector cells (such as Th1,
 312 Th2, or Th17 cells) (36). Therefore, Tfh cells are a specialized subset of CD4⁺ T cells
 313 that help B cells respond to antigens (37), which is, in turn, depends on the expression
 314 of transcriptional factor B cell lymphoma 6 (BCL6) (38). In the past decade, several
 315 studies have revealed a potential connection between Tfh cells and infiltrated tumors.
 316 Amé-Thomas et al. (39) demonstrated that Tfh cells protect follicular lymphoma
 317 malignant B cells from spontaneous and rituximab-induced apoptosis by upregulating
 318 CD40L and IL-4, which might lead to a worse prognosis. In non-small cell lung
 319 cancer (NSCLC) tumor tissues, the proportion of Tfh cells is increased, suggesting
 320 that Tfh cells might play an important role in estimating the poor survival of NSCLC
 321 patients (40). In addition, Tfh cell abundance is known to improve prognosis of
 322 patients with breast cancer or colorectal cancer (41, 42), which indicates the value of
 323 Tfh cells against tumors through immune responses.

324 Mast cells, both resting and activated, are large granulated innate immune cells
 325 found predominantly in sites between the host and its external environment, such as
 326 skin, respiratory mucosa, and the gastrointestinal tract (43). The activation of mast
 327 cells is related to various stimuli received by numerous receptors on the cell surface,
 328 such as pathogens, neuropeptides, cytokines, growth factors, toxins, basic compounds,
 329 complement, immune complexes, etc. (44). Recent studies have shown that the
 330 association between mast cells and cancer is two-sided, including both involvement in,
 331 and protection against, tumor progression. Xu et al. (45) constructed a
 332 prognosis-associated microRNA–mast cell network in lung adenocarcinoma, and
 333 found resting mast cell numbers were closely related to better overall survival and
 334 disease-free survival (DFS), while activated mast cells were related to poor survival.

335 miR-30a and miR-550a are also involved in the regulation of immune response by
336 acting as the promoter and suppressor of resting mast cells, respectively. In contrast,
337 mast cells in hepatocellular carcinoma are mostly resting, inactivation of mast cells
338 can promote immune escape, which is beneficial to tumor growth (46).

339 Our research inevitably has some limitations that should be recognized. First, our
340 research data was obtained from public databases. The limited data means that the
341 clinical pathological parameters are incomplete, which can lead to potential errors and
342 biases. Secondly, we have not taken the heterogeneity of the immune
343 microenvironment associated with the location of immune infiltration into
344 consideration. In other words, the accuracy and applicability of the prediction models
345 will be affected by the heterogeneity of tissue subtypes. In addition, the data series
346 used in this study are all from Western countries, so applying the research conclusions
347 to Asian countries has certain bias and may be inappropriate. As well, the lack of cell
348 markers for resting mast cells leads to incomplete validation in our study. Lastly, this
349 study is not a biological mechanism research, as it lacks experiments on the
350 interaction mechanisms between ceRNA and immune cells. Despite limitations of the
351 study, we did combine tumor infiltrating immune cells with a ceRNA network for
352 analysis in KIRC, which not only constructed two nomograms with clinical
353 predictive value, but also identified a correlation between two key prognostic
354 molecules and two prognosis-related immune cells, providing novel directions for
355 future research.

356

357 **Conclusions**

358 Based on tumor-infiltrating immune cells and ceRNA networks, we constructed two
359 nomograms to predict survival of KIRC patients. The high AUC values we obtained

360 reflect the utility of this approach, which provides clinicians with more
 361 comprehensive clinical information through the models to improve individual
 362 management of KIRC patients. In addition, our study suggests that LINC00894,
 363 KIAA1324, Tfh cells and resting mast cells are significantly related to the prognosis
 364 of KIRC patients and we infer that LINC00894 and KIAA1324 might interact with
 365 Tfh cells and resting mast cells to affect the progression of KIRC. This study also
 366 provides new ideas for the pathogenesis and clinical treatment of KIRC.

367

368 **Author contribution**

369 ZQ and NL conceived the idea and designed the study. LD conducted the data
 370 analysis and visualization. PW performed the data interpretation and literature
 371 collection. LD and NL wrote the manuscript. ZQ and NL contributed to the revision
 372 of the manuscript draft. All authors read and approved the final manuscript.

373

374 **Data availability statement**

375 The dataset (TCGA-KIRC) analyzed in this study is publicly available in TCGA
 376 (<https://tcga-data.nci.nih.gov/tcga/>).

377

378 **Declaration of competing interest**

379 We declare that no potential competing interests exist.

380

381 Acknowledgement

382 This work was supported by National Natural Science Foundation of China (No.
383 81872584) and (No. 81472941), National 863 Young Scientist Program (No.
384 2015AA020940), Key Scientific Research Project Plan of Henan Province (No.
385 21A330001), Natural Science Foundation of Guangdong Province (No.
386 2016A030313138), Key Projects of Guangzhou Science and Technology Program
387 (No. 201704020056), Interdisciplinary Research for First-class Discipline
388 Construction Project of Henan University (No. 2019YLXKJC04) and Scientific
389 Research Project for University of Education Bureau of Guangzhou (No. 201831841).

390

391 References

- 392 1. R. L. Siegel, K. D. Miller and A. Jemal: Cancer statistics, 2018. *CA: A Cancer*
393 *Journal for Clinicians*, 68(1), 7-30 (2018) doi:10.3322/caac.21442
- 394 2. J. J. Hsieh, M. P. Purdue, S. Signoretti, C. Swanton, L. Albiges, M. Schmidinger,
395 D. Y. Heng, J. Larkin and V. Ficarra: Renal cell carcinoma. *Nature Reviews Disease*
396 *Primers*, 3(1), 17009 (2017) doi:10.1038/nrdp.2017.9
- 397 3. W. Xiao, X. Wang, T. Wang and J. Xing: Overexpression of BMP1 reflects poor
398 prognosis in clear cell renal cell carcinoma. *Cancer gene therapy*, 27(5), 330-340
399 (2020) doi:10.1038/s41417-019-0107-9
- 400 4. J. J. Morrissey, V. M. Mellnick, J. Luo, M. J. Siegel, R. S. Figenschau, S. Bhayani
401 and E. D. Kharasch: Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations
402 as Biomarkers to Screen for Renal Cell Carcinoma: A Prospective Cohort Study.
403 *JAMA Oncology*, 1(2), 204-212 (2015) doi:10.1001/jamaoncol.2015.0213
- 404 5. T. Nagano and P. Fraser: No-Nonsense Functions for Long Noncoding RNAs.
405 *Cell*, 145(2), 178-181 (2011) doi:<https://doi.org/10.1016/j.cell.2011.03.014>
- 406 6. J. J. Quinn and H. Y. Chang: Unique features of long non-coding RNA biogenesis
407 and function. *Nature Reviews Genetics*, 17(1), 47-62 (2016) doi:10.1038/nrg.2015.10
- 408 7. Y. Tay, J. Rinn and P. P. Pandolfi: The multilayered complexity of ceRNA
409 crosstalk and competition. *Nature*, 505(7483), 344-352 (2014)
410 doi:10.1038/nature12986

- 411 8. W. Hong, Y. Gu, R. Guan, D. Xie, H. Zhou and M. Yu: Pan-cancer analysis of the
412 CASP gene family in relation to survival, tumor-infiltrating immune cells and
413 therapeutic targets. *Genomics*, 112(6), 4304-4315 (2020)
414 doi:<https://doi.org/10.1016/j.ygeno.2020.07.026>
- 415 9. Y. Gao, S. Chen, S. Vafaei and X. Zhong: Tumor-Infiltrating Immune Cell
416 Signature Predicts the Prognosis and Chemosensitivity of Patients With Pancreatic
417 Ductal Adenocarcinoma. *Frontiers in oncology*, 10, 557638-557638 (2020)
418 doi:10.3389/fonc.2020.557638
- 419 10. M. Xu, X. Xu, B. Pan, X. Chen, K. Lin, K. Zeng, X. Liu, T. Xu, L. Sun, J. Qin, B.
420 He, Y. Pan, H. Sun and S. Wang: LncRNA SATB2-AS1 inhibits tumor metastasis and
421 affects the tumor immune cell microenvironment in colorectal cancer by regulating
422 SATB2. *Molecular Cancer*, 18(1), 135 (2019) doi:10.1186/s12943-019-1063-6
- 423 11. D. Huang, J. Chen, L. Yang, Q. Ouyang, J. Li, L. Lao, J. Zhao, J. Liu, Y. Lu, Y.
424 Xing, F. Chen, F. Su, H. Yao, Q. Liu, S. Su and E. Song: NKILA lncRNA promotes
425 tumor immune evasion by sensitizing T cells to activation-induced cell death. *Nature*
426 *Immunology*, 19(10), 1112-1125 (2018) doi:10.1038/s41590-018-0207-y
- 427 12. J. Cao, R. Dong, L. Jiang, Y. Gong, M. Yuan, J. You, W. Meng, Z. Chen, N.
428 Zhang, Q. Weng, H. Zhu, Q. He, M. Ying and B. Yang: LncRNA-MM2P Identified as
429 a Modulator of Macrophage M2 Polarization. *Cancer Immunology Research*, 7(2),
430 292-305 (2019) doi:10.1158/2326-6066.Cir-18-0145
- 431 13. M. I. Love, W. Huber and S. Anders: Moderated estimation of fold change and
432 dispersion for RNA-seq data with DESeq2. *Genome Biology*, 15(12), 550 (2014)
433 doi:10.1186/s13059-014-0550-8
- 434 14. J.-H. Li, S. Liu, H. Zhou, L.-H. Qu and J.-H. Yang: starBase v2.0: decoding
435 miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from
436 large-scale CLIP-Seq data. *Nucleic Acids Research*, 42(D1), D92-D97 (2014)
437 doi:10.1093/nar/gkt1248
- 438 15. J.-H. Yang, J.-H. Li, P. Shao, H. Zhou, Y.-Q. Chen and L.-H. Qu: starBase: a
439 database for exploring microRNA-mRNA interaction maps from Argonaute
440 CLIP-Seq and Degradome-Seq data. *Nucleic Acids Research*, 39(suppl_1),
441 D202-D209 (2011) doi:10.1093/nar/gkq1056
- 442 16. P. Shannon, A. Markiel, O. Ozier, N. S. Baliga, J. T. Wang, D. Ramage, N. Amin,
443 B. Schwikowski and T. Ideker: Cytoscape: a software environment for integrated
444 models of biomolecular interaction networks. *Genome research*, 13(11), 2498-2504
445 (2003) doi:10.1101/gr.1239303
- 446 17. A. M. Newman, C. L. Liu, M. R. Green, A. J. Gentles, W. Feng, Y. Xu, C. D.
447 Hoang, M. Diehn and A. A. Alizadeh: Robust enumeration of cell subsets from tissue
448 expression profiles. *Nature methods*, 12(5), 453-457 (2015) doi:10.1038/nmeth.3337
- 449 18. X. Zhang, M. Wang, H. Sun, T. Zhu and X. Wang: Downregulation of
450 LINC00894-002 Contributes to Tamoxifen Resistance by Enhancing the TGF- β
451 Signaling Pathway. *Biochemistry (Moscow)*, 83(5), 603-611 (2018)
452 doi:10.1134/S0006297918050139

19. T. Liu, J. Sui, Y. Zhang, X. M. Zhang, W. J. Wu, S. Yang, S. Y. Xu, W. W. Hong, H. Peng, L. H. Yin, Y. P. Pu and G. Y. Liang: Comprehensive analysis of a novel lncRNA profile reveals potential prognostic biomarkers in clear cell renal cell carcinoma. *Oncol Rep*, 40(3), 1503-1514 (2018) doi:10.3892/or.2018.6540
20. A. Ward, A. Balwierz, J. D. Zhang, M. Küblbeck, Y. Pawitan, T. Hielscher, S. Wiemann and Ö. Sahin: Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. *Oncogene*, 32(9), 1173-1182 (2013) doi:10.1038/onc.2012.128
21. S.-M. Park, A. B. Gaur, E. Lengyel and M. E. Peter: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. *Genes & development*, 22(7), 894-907 (2008) doi:10.1101/gad.1640608
22. M. Farhan, M. Aatif, P. Dandawate and A. Ahmad: Non-coding RNAs as Mediators of Tamoxifen Resistance in Breast Cancers. In: *Breast Cancer Metastasis and Drug Resistance: Challenges and Progress*. Ed A. Ahmad. Springer International Publishing, Cham (2019) doi:10.1007/978-3-030-20301-6_11
23. L. Huang, G. Liang, Q. Zhang and W. Zhao: The Role of Long Noncoding RNAs in Antiestrogen Resistance in Breast Cancer: An Overview and Update. *Journal of breast cancer*, 23(2), 129-140 (2020) doi:10.4048/jbc.2020.23.e10
24. X. Lai, S. K. Gupta, U. Schmitz, S. Marquardt, S. Knoll, A. Spitschak, O. Wolkenhauer, B. M. Pützer and J. Vera: MiR-205-5p and miR-342-3p cooperate in the repression of the E2F1 transcription factor in the context of anticancer chemotherapy resistance. *Theranostics*, 8(4), 1106-1120 (2018) doi:10.7150/thno.19904
25. Y. Qin, X. Zhou, C. Huang, L. Li, H. Liu, N. Liang, Y. Chen, D. Ma, Z. Han, X. Xu, J. He and S. Li: Serum miR-342-3p is a novel diagnostic and prognostic biomarker for non-small cell lung cancer. *International journal of clinical and experimental pathology*, 11(5), 2742-2748 (2018)
26. X. Xue, X. Fei, W. Hou, Y. Zhang, L. Liu and R. Hu: miR-342-3p suppresses cell proliferation and migration by targeting AGR2 in non-small cell lung cancer. *Cancer Letters*, 412, 170-178 (2018) doi:<https://doi.org/10.1016/j.canlet.2017.10.024>
27. X. Meng, J. Ma, B. Wang, X. Wu and Z. Liu: Long non-coding RNA OIP5-AS1 promotes pancreatic cancer cell growth through sponging miR-342-3p via AKT/ERK signaling pathway. *Journal of Physiology and Biochemistry*, 76(2), 301-315 (2020) doi:10.1007/s13105-020-00734-4
28. F. Zheng, H. Zhang and J. Lu: Identification of potential microRNAs and their targets in promoting gefitinib resistance by integrative network analysis. *Journal of thoracic disease*, 11(12), 5535-5546 (2019) doi:10.21037/jtd.2019.11.25
29. L. Deng, R. R. Broaddus, A. McCampbell, G. L. Shipley, D. S. Loose, G. M. Stancel, J. H. Pickar and P. J. A. Davies: Identification of a Novel Estrogen-Regulated Gene, EIG121, Induced by Hormone Replacement Therapy and Differentially Expressed in Type I and Type II Endometrial Cancer. *Clinical Cancer Research*, 11(23), 8258 (2005) doi:10.1158/1078-0432.CCR-05-1189

495 30. J. M. Kang, S. Park, S. J. Kim, H. Kim, B. Lee, J. Kim, J. Park, S. T. Kim, H.-K.
496 Yang, W. H. Kim and S.-J. Kim: KIAA1324 Suppresses Gastric Cancer Progression
497 by Inhibiting the Oncoprotein GRP78. *Cancer Research*, 75(15), 3087 (2015)
498 doi:10.1158/0008-5472.CAN-14-3751
499 31. S. N. Westin, R. R. Broaddus, L. Deng, A. McCampbell, K. H. Lu, R. A. Lacour,
500 M. R. Milam, D. L. Urbauer, P. Mueller, J. H. Pickar and D. S. Loose: Molecular
501 clustering of endometrial carcinoma based on estrogen-induced gene expression.
502 *Cancer biology & therapy*, 8(22), 2126-2135 (2009) doi:10.4161/cbt.8.22.9740
503 32. D. S. Oh, M. A. Troester, J. Usary, Z. Hu, X. He, C. Fan, J. Wu, L. A. Carey and
504 C. M. Perou: Estrogen-Regulated Genes Predict Survival in Hormone
505 Receptor-Positive Breast Cancers. *Journal of Clinical Oncology*, 24(11), 1656-1664
506 (2006) doi:10.1200/JCO.2005.03.2755
507 33. M. P. Schlumbrecht, S.-S. Xie, G. L. Shipley, D. L. Urbauer and R. R. Broaddus:
508 Molecular clustering based on ER α and EIG121 predicts survival in high-grade serous
509 carcinoma of the ovary/peritoneum. *Modern Pathology*, 24(3), 453-462 (2011)
510 doi:10.1038/modpathol.2010.211
511 34. L. Deng, J. Feng and R. R. Broaddus: The novel estrogen-induced gene EIG121
512 regulates autophagy and promotes cell survival under stress. *Cell death & disease*,
513 1(4), e32-e32 (2010) doi:10.1038/cddis.2010.9
514 35. G. Zhu, L. Pei, H. Yin, F. Lin, X. Li, X. Zhu, W. He and X. Gou: Profiles of
515 tumor-infiltrating immune cells in renal cell carcinoma and their clinical implications.
516 *Oncology letters*, 18(5), 5235-5242 (2019) doi:10.3892/ol.2019.10896
517 36. S. Crotty: Follicular Helper CD4 T Cells (TFH). *Annual Review of Immunology*,
518 29(1), 621-663 (2011) doi:10.1146/annurev-immunol-031210-101400
519 37. S. Crotty: T Follicular Helper Cell Biology: A Decade of Discovery and Diseases.
520 *Immunity*, 50(5), 1132-1148 (2019) doi:10.1016/j.immuni.2019.04.011
521 38. R. J. Johnston, A. C. Poholek, D. DiToro, I. Yusuf, D. Eto, B. Barnett, A. L. Dent,
522 J. Craft and S. Crotty: Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of
523 T follicular helper cell differentiation. *Science (New York, N.Y.)*, 325(5943),
524 1006-1010 (2009) doi:10.1126/science.1175870
525 39. P. Amé-Thomas, J. Le Priol, H. Yssel, G. Caron, C. Pangault, R. Jean, N. Martin,
526 T. Marafioti, P. Gaulard, T. Lamy, T. Fest, G. Semana and K. Tarte: Characterization
527 of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of
528 malignant B cells. *Leukemia*, 26(5), 1053-1063 (2012) doi:10.1038/leu.2011.301
529 40. Z. Guo, H. Liang, Y. Xu, L. Liu, X. Ren, S. Zhang, S. Wei and P. Xu: The Role of
530 Circulating T Follicular Helper Cells and Regulatory Cells in Non-Small Cell Lung
531 Cancer Patients. *Scandinavian Journal of Immunology*, 86(2), 107-112 (2017)
532 doi:<https://doi.org/10.1111/sji.12566>
533 41. C. Gu-Trantien, S. Loi, S. Garaud, C. Equeter, M. Libin, A. de Wind, M. Ravoet,
534 H. Le Buanec, C. Sibille, G. Manfouo-Foutsop, I. Veys, B. Haibe-Kains, S. K. Singhal,
535 S. Michiels, F. Rothé, R. Salgado, H. Duvillier, M. Ignatiadis, C. Desmedt, D. Bron, D.
536 Larsimont, M. Piccart, C. Sotiriou and K. Willard-Gallo: CD4 \square follicular helper T

537 cell infiltration predicts breast cancer survival. *The Journal of clinical investigation*,
538 123(7), 2873-2892 (2013) doi:10.1172/JCI67428

539 42. G. Bindea, B. Mlecnik, M. Tosolini, A. Kirilovsky, M. Waldner, Anna C. Obenauf,
540 H. Angell, T. Fredriksen, L. Lafontaine, A. Berger, P. Bruneval, Wolf H. Fridman, C.
541 Becker, F. Pagès, Michael R. Speicher, Z. Trajanoski and J. Galon: Spatiotemporal
542 Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human
543 Cancer. *Immunity*, 39(4), 782-795 (2013)
544 doi:<https://doi.org/10.1016/j.immuni.2013.10.003>

545 43. B. Frossi, F. Mion, C. Tripodo, M. P. Colombo and C. E. Pucillo: Rheostatic
546 Functions of Mast Cells in the Control of Innate and Adaptive Immune Responses.
547 *Trends in Immunology*, 38(9), 648-656 (2017)
548 doi:<https://doi.org/10.1016/j.it.2017.04.001>

549 44. E. Z. M. da Silva, M. C. Jamur and C. Oliver: Mast cell function: a new vision of
550 an old cell. *The journal of histochemistry and cytochemistry : official journal of the*
551 *Histochemistry Society*, 62(10), 698-738 (2014) doi:10.1369/0022155414545334

552 45. C. Wang, X. Tang, J. Wang and Y. Xu: Patterns of immune infiltration in lung
553 adenocarcinoma revealed a prognosis-associated microRNA–mast cells network.
554 *Human Cell*, 33(1), 205-219 (2020) doi:10.1007/s13577-019-00300-1

555 46. N. Rohr-Udilova, F. Klinglmüller, R. Schulte-Hermann, J. Stift, M. Herac, M.
556 Salzmann, F. Finotello, G. Timelthaler, G. Oberhuber, M. Pinter, T. Reiberger, E.
557 Jensen-Jarolim, R. Eferl and M. Trauner: Deviations of the immune cell landscape
558 between healthy liver and hepatocellular carcinoma. *Scientific reports*, 8(1),
559 6220-6220 (2018) doi:10.1038/s41598-018-24437-5

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575 **Figure Captions**

576 **Figure 1** Flowchart of the analysis process.

577

578 **Figure 2** Genes differentially expressed in 506 KIRC tissues versus 71 normal
579 adjacent tissues. Provided are the heatmap (a) and the volcano plot (b) of 357
580 differentially expressed lncRNAs between the two groups; the heatmap (c) and the
581 volcano plot (d) of 132 differentially expressed miRNAs between the two groups; and
582 the heatmap (e) and the volcano plot (f) of 3092 differentially expressed
583 protein-coding genes between the two groups; and the composition of differentially
584 expressed genes (g). All differentially expressed genes had a log (fold-change) > 1.0
585 or < -1.0 and the overall of FDR < 0.05.

586

587 **Figure 3** (a) The KIRC related ceRNA network consisting of 12 lncRNAs, 25
588 miRNAs and 136 mRNAs. (b-j) The K-M survival curves of the top three lncRNAs,
589 miRNAs and mRNAs: PVT1 (b), AC005154.1 (c), AC015813.1 (d), hsa-miR-21-5p
590 (e), hsa-miR-130b-3p (f), hsa-miR-204-5p (g), MXD3 (h), VPS13D (i) and KCNN4
591 (j).

592

593 **Figure 4** The Cox proportional hazards regression model (a) based on RNAs screened

594 by Lasso regression analysis (b and c) in the ceRNA network. Seven potential
595 prognosis related RNAs were integrated into the Cox proportional hazards regression
596 model. The nomogram (e) was constructed based on the model. The ROC (d) and
597 calibration curves (f) indicate the acceptable accuracy (AUCs of 1, 3 and 5-year
598 survivals: 0.779, 0.747 and 0.772) and discrimination of the nomogram.
599 $*P < 0.05$; $**P < 0.010$; $***P < 0.001$.

600

601 **Figure 5** The composition (a) and heatmap (b) of immune cells estimated by the
602 CIBERSORT algorithm in five normal adjacent tissues and 206 KIRC tissues. The
603 violin plot of immune cells (c) compares cells' proportion between the two groups.

604

605 **Figure 6** The Cox proportional hazards regression model (a) based on immune cells
606 screened by Lasso regression analysis (b and c). Tfh cells and resting mast cells were
607 integrated into the Cox proportional hazards regression model. The nomogram (e) was
608 constructed based on the model. The ROC (d) and the calibration curves (f) indicate
609 the acceptable accuracy (AUCs of 1, 3 and 5-year survivals: 0.603, 0.642 and 0.607)
610 and discrimination of the nomogram.

611 $*P < 0.05$; $**P < 0.010$; $***P < 0.001$.

612

613 **Figure 7** Co-expression heatmap of all immune cells in KIRC (a); the co-expression
614 heatmap of the RNAs and immune cells in the two Cox proportional hazards
615 regression models (b); the significant results of Pearson correlation coefficients
616 between the RNAs and immune cells: Tfh cells and LINC00894 (c); Tfh cells and
617 KIAA1324 (d); resting mast cells and LINC00894 (e); resting mast cells and
618 KIAA1324 (f).

619 **Table**

620

Table 1 Hypergeometric testing and correlation analysis results of ceRNAs pairs

lncRNAs	mRNAs	miRNAs	Hypergeometric test <i>P</i>	Correlation <i>P</i>
AC005154.1	KAT2A	hsa-miR-122-5p	0.042851557	1.32E-95
AC015813.1	SLC16A1	hsa-miR-590-3p	0.0433213	0.019445968
AC015813.1	FHOD1	hsa-miR-590-3p	0.007220217	4.09E-19
AC015813.1	E2F8	hsa-miR-590-3p	0.025270758	1.22E-09
AC015813.1	SERPINB9	hsa-miR-590-3p	0.025270758	0.000636067
AC015813.1	COL5A2	hsa-miR-590-3p	0.014440433	0.015398545
AC015813.1	BRIP1	hsa-miR-590-3p	0.003610108	5.18E-09
AC015813.1	ESCO2	hsa-miR-590-3p	0.02166065	0.009163956
AC015813.1	TXLNB	hsa-miR-590-3p	0.003610108	0.020621823

AC015813.1	PSTPIP2	hsa-miR-590-3p	0.003610108	0.000108913
AC015813.1	SNRNP70	hsa-miR-590-3p	0.003610108	4.80E-73
AC016876.2	TNFRSF10B	hsa-miR-133a-3p	0.003810813	9.33E-39
AC016876.2	MYO9B	hsa-miR-133a-3p	0.000392403	1.06E-53
AC016876.2	PREX1	hsa-miR-133a-3p	0.013191013	2.17E-22
AC016876.2	CAPN15	hsa-miR-133a-3p	0.027474351	1.51E-34
AC016876.2	CORO1C	hsa-miR-133a-3p	0.001461641	2.06E-36
AC016876.2	FJX1	hsa-miR-133a-3p	0.036258784	6.66E-19
AC016876.2	NDRG1	hsa-miR-133a-3p	0.010361047	1.00E-11
AC016876.2	VKORC1	hsa-miR-133a-3p	0.001165794	1.01E-27
AC016876.2	TMEM200B	hsa-miR-133a-3p	0.013191013	9.12E-19
AC016876.2	RSRP1	hsa-miR-133a-3p	0.000881161	6.23E-07

C1RL-AS1	SCARB1	hsa-miR-16-5p	0.001438811	1.64E-42
C1RL-AS1	VEGFA	hsa-miR-16-5p	0.030764401	2.81E-61
C1RL-AS1	AHNAK2	hsa-miR-16-5p	0.000392403	7.17E-21
C1RL-AS1	PTHLH	hsa-miR-16-5p	0.009888558	1.10E-07
C1RL-AS1	RELT	hsa-miR-16-5p	0.000732486	3.61E-14
C1RL-AS1	PFKFB4	hsa-miR-16-5p	0.004002511	6.80E-27
C1RL-AS1	CCND1	hsa-miR-16-5p	0.046303563	7.81E-25
C1RL-AS1	APLN	hsa-miR-16-5p	0.000549364	2.74E-25
C1RL-AS1	SH2D2A	hsa-miR-16-5p	0.000732486	7.13E-19
C1RL-AS1	SEL1L3	hsa-miR-16-5p	0.012975462	1.23E-23
C1RL-AS1	UNC5B	hsa-miR-16-5p	0.000392403	1.58E-15
C1RL-AS1	PHLDA3	hsa-miR-16-5p	0.001177209	0.000714118

C1RL-AS1	SLC41A2	hsa-miR-16-5p	0.000941767	1.16E-10
C1RL-AS1	GRB10	hsa-miR-16-5p	0.022523937	4.08E-21
C1RL-AS1	SLC2A3	hsa-miR-16-5p	0.013812588	1.39E-09
C1RL-AS1	MYBL1	hsa-miR-16-5p	0.049468948	1.21E-08
C1RL-AS1	ANLN	hsa-miR-16-5p	0.004002511	7.40E-05
C1RL-AS1	OTOGL	hsa-miR-16-5p	0.000392403	1.38E-08
C1RL-AS1	KCNJ2	hsa-miR-16-5p	0.019384712	9.72E-07
C1RL-AS1	CNTNAP1	hsa-miR-16-5p	0.003139225	6.23E-12
C1RL-AS1	NRARP	hsa-miR-16-5p	0.023622665	4.17E-13
C1RL-AS1	CREB5	hsa-miR-16-5p	0.013812588	5.44E-48
C1RL-AS1	ATAD5	hsa-miR-16-5p	0.042928897	2.56E-37
C1RL-AS1	INSR	hsa-miR-16-5p	0.009182232	1.03E-20

C1RL-AS1	SIPA1L2	hsa-miR-16-5p	0.006043007	9.08E-08
C1RL-AS1	AATK	hsa-miR-16-5p	0.000549364	1.52E-28
C1RL-AS1	RFLNB	hsa-miR-16-5p	0.000941767	5.34E-05
C1RL-AS1	SPRY4	hsa-miR-16-5p	0.002746822	8.52E-14
C1RL-AS1	ARL10	hsa-miR-16-5p	0.001438811	1.17E-11
C1RL-AS1	ANKRD13B	hsa-miR-16-5p	0.003139225	7.32E-16
C1RL-AS1	SNAP25	hsa-miR-16-5p	0.002380579	1.30E-19
C1RL-AS1	LY6E	hsa-miR-16-5p	0.000941767	1.68E-17
C1RL-AS1	CDK5R1	hsa-miR-16-5p	0.013812588	1.69E-16
C1RL-AS1	CLCN5	hsa-miR-16-5p	0.006618532	0.020236846
C1RL-AS1	BDNF	hsa-miR-16-5p	0.010621043	8.30E-09
C1RL-AS1	IRX3	hsa-miR-16-5p	0.000732486	1.79E-37

C1RL-AS1	PLAGL1	hsa-miR-16-5p	0.004473395	1.30E-23
C1RL-AS1	IRF4	hsa-miR-16-5p	0.004970439	2.67E-12
C1RL-AS1	TSPYL2	hsa-miR-16-5p	0.002380579	1.01E-20
C1RL-AS1	TLL1	hsa-miR-16-5p	0.007848062	5.19E-19
C1RL-AS1	KCNN4	hsa-miR-16-5p	0.000732486	4.96E-09
C1RL-AS1	TRIM36	hsa-miR-16-5p	0.015565322	0.000352309
C1RL-AS1	CBFA2T3	hsa-miR-16-5p	0.004970439	6.86E-13
C1RL-AS1	TSC22D3	hsa-miR-16-5p	0.012975462	3.07E-05
C1RL-AS1	SNCG	hsa-miR-16-5p	0.001726574	0.02336615
EPB41L4A-AS1	TNFRSF10B	hsa-miR-93-5p	0.005296055	0.000309792
EPB41L4A-AS1	IKBIP	hsa-miR-93-5p	0.049992152	1.07E-06
H19	EGLN3	hsa-miR-130b-3p	0.025364366	0.030923622

H19	UXS1	hsa-miR-130b-3p	0.017341521	0.000663666
H19	USP46	hsa-miR-130b-3p	0.024521918	0.043104031
H19	ACSL4	hsa-miR-130b-3p	0.049356887	0.046472711
H19	LDLRAD3	hsa-miR-130b-3p	0.017341521	2.91E-06
H19	BMP6	hsa-miR-130b-3p	0.021136246	1.44E-05
H19	RASD1	hsa-miR-130b-3p	0.001092495	0.000237995
H19	NHSL1	hsa-miR-130b-3p	0.002162624	0.000635296
H19	C8orf4	hsa-miR-130b-3p	0.040677495	1.83E-10
H19	MAP3K12	hsa-miR-130b-3p	0.000287237	0.006322847
H19	VPS13D	hsa-miR-130b-3p	0.00310273	0.022110203
H19	PXDN	hsa-miR-130b-3p	0.001415171	2.64E-12
H19	PMEPA1	hsa-miR-130b-3p	0.001092495	2.21E-10

H19	WNK3	hsa-miR-130b-3p	0.000207327	0.000409846
H19	PFKFB3	hsa-miR-130b-3p	0.004199543	0.001757017
H19	TCF4	hsa-miR-130b-3p	0.000309855	2.83E-07
H19	HECW2	hsa-miR-130b-3p	0.001092495	0.000515485
H19	LRRC41	hsa-miR-130b-3p	0.008478302	0.004641957
H19	KLHL3	hsa-miR-130b-3p	0.035134428	0.004796761
H19	LDLR	hsa-miR-130b-3p	0.002491825	6.36E-13
H19	SCARA3	hsa-miR-130b-3p	0.005054152	6.50E-06
LINC00893	SCARB1	hsa-miR-125b-5p, hsa-miR-125a-5p	0.001438811	0.000105621
LINC00893	VEGFA	hsa-miR-125b-5p, hsa-miR-125a-5p	0.030764401	8.10E-26
LINC00893	MYEOV	hsa-miR-125b-5p	0.014414273	6.39E-05
LINC00893	SOX11	hsa-miR-125b-5p, hsa-miR-125a-5p	0.015565322	9.42E-07

LINC00893	PRDM1	hsa-miR-125b-5p, hsa-miR-125a-5p	0.032046251	0.001791829
LINC00893	GJC1	hsa-miR-125b-5p, hsa-miR-125a-5p	0.003139225	1.58E-05
LINC00893	OLFML2A	hsa-miR-125b-5p, hsa-miR-125a-5p	0.000156961	0.009879398
LINC00893	LIMD2	hsa-miR-125b-5p, hsa-miR-125a-5p	0.006043007	8.66E-13
LINC00893	GRB10	hsa-miR-125b-5p, hsa-miR-125a-5p	0.022523937	0.004617551
LINC00893	TNFAIP3	hsa-miR-125b-5p, hsa-miR-125a-5p	0.02040496	0.000292635
LINC00893	KMT5C	hsa-miR-125b-5p, hsa-miR-125a-5p	0.006618532	1.47E-81
LINC00893	PDE7A	hsa-miR-125b-5p, hsa-miR-125a-5p	0.019384712	2.94E-13
LINC00893	PLAGL1	hsa-miR-125b-5p, hsa-miR-125a-5p	0.004473395	1.50E-09
LINC00893	IRF4	hsa-miR-125b-5p, hsa-miR-125a-5p	0.004970439	8.51E-05
LINC00893	FAM118A	hsa-miR-125b-5p, hsa-miR-125a-5p	0.005493643	1.23E-43
LINC00894	GRIN2D	hsa-miR-342-3p	0.02166065	0.020258812

MALAT1	ZNF395	hsa-miR-429, hsa-miR-200c-3p	0.033565927	0.009006143
MALAT1	SCD	hsa-miR-200b-3p, hsa-miR-200a-3p, hsa-miR-429, hsa-miR-200c-3p, hsa-miR-141-3p	0.039289444	0.011807116
MALAT1	EZH2	hsa-miR-217	0.039289444	6.86E-14
MALAT1	MXD3	hsa-miR-200b-3p, hsa-miR-429, hsa-miR-200c-3p	0.001707738	3.90E-34
MALAT1	BAZ1A	hsa-miR-590-3p	0.018390826	7.26E-05
MALAT1	SIX1	hsa-miR-200b-3p, hsa-miR-200a-3p, hsa-miR-429, hsa-miR-200c-3p, hsa-miR-141-3p, hsa-miR-590-3p	0.00025153	4.87E-06
MALAT1	KCNJ2	hsa-miR-1-3p, hsa-miR-1271-5p, hsa-miR-590-3p	0.000680978	0.01227854
MALAT1	RUNX2	hsa-miR-203a-3p, hsa-miR-217, hsa-miR-590-3p	0.027070651	0.007921587
MALAT1	PDE7A	hsa-miR-1-3p	0.031465278	1.64E-07
MALAT1	CCND2	hsa-miR-200a-3p, hsa-miR-141-3p, hsa-miR-1-3p,	0.002367103	0.005749454

		hsa-miR-1271-5p		
MALAT1	FOXF1	hsa-miR-200b-3p, hsa-miR-429, hsa-miR-200c-3p	0.033565927	0.001701238
MALAT1	KIAA1324	hsa-miR-1271-5p	0.040612149	0.018453328
NEAT1	STC2	hsa-miR-181b-5p, hsa-miR-204-5p	0.005508592	0.022782701
NEAT1	GJC1	hsa-let-7e-5p, hsa-let-7g-5p	0.010508709	0.038550157
NEAT1	ADM	hsa-miR-181b-5p	0.028501136	9.33E-08
NEAT1	EZH2	hsa-let-7e-5p, hsa-let-7g-5p	0.008654278	1.27E-12
NEAT1	AURKB	hsa-let-7e-5p, hsa-let-7g-5p	0.00048449	0.032101352
NEAT1	KIF21B	hsa-let-7e-5p, hsa-let-7g-5p	0.003786827	3.94E-06
NEAT1	INTS6L	hsa-let-7e-5p, hsa-let-7g-5p	0.001348287	1.00E-46
NEAT1	DTX2	hsa-let-7e-5p, hsa-let-7g-5p	0.022864398	0.003873252
NEAT1	LIMD2	hsa-let-7e-5p, hsa-let-7g-5p	0.001852057	0.023584192

NEAT1	NGF	hsa-let-7e-5p, hsa-let-7g-5p	0.00048449	0.036481826
NEAT1	POLQ	hsa-miR-181b-5p, hsa-let-7e-5p	0.026346413	4.13E-05
NEAT1	POU2F2	hsa-let-7e-5p, hsa-let-7g-5p	0.00772659	0.046579228
NEAT1	APBB3	hsa-let-7e-5p, hsa-let-7g-5p	0.003786827	1.03E-93
NEAT1	MAPK11	hsa-let-7e-5p, hsa-let-7g-5p	0.00048449	0.020903367
NEAT1	FBXO41	hsa-miR-181b-5p	0.000291346	0.00718285
NEAT1	PITPNM3	hsa-let-7e-5p, hsa-let-7g-5p	0.022864398	0.000826877
NEAT1	NPHP3	hsa-let-7e-5p, hsa-let-7g-5p	0.022864398	7.31E-68
NEAT1	DNA2	hsa-let-7e-5p, hsa-let-7g-5p	0.003786827	1.69E-34
NEAT1	AMT	hsa-let-7e-5p, hsa-let-7g-5p	0.000906364	0.001503922
NEAT1	SLC25A37	hsa-miR-181b-5p	0.002491825	1.48E-28
NEAT1	FAM118A	hsa-let-7e-5p, hsa-let-7g-5p	0.034971322	7.22E-34

NEAT1	AASS	hsa-let-7e-5p, hsa-let-7g-5p	0.00048449	1.39E-05
NEAT1	CELSR3	hsa-miR-181b-5p, hsa-miR-204-5p	0.00026878	5.77E-21
NEAT1	KIFC2	hsa-let-7e-5p, hsa-let-7g-5p	0.002491825	4.59E-65
NEAT1	RNF165	hsa-let-7e-5p, hsa-let-7g-5p	0.00587435	2.76E-05
NEAT1	SLC25A27	hsa-let-7e-5p, hsa-let-7g-5p	0.001554187	2.36E-89
PVT1	TNFRSF10B	hsa-miR-93-5p	0.005296055	1.15E-70
PVT1	IKBIP	hsa-miR-93-5p	0.049992152	4.69E-68
PVT1	TET3	hsa-miR-93-5p, hsa-miR-20b-5p	0.000351901	6.58E-37
PVT1	CCND2	hsa-miR-93-5p, hsa-miR-20b-5p	0.000180512	2.67E-22
SNHG1	NETO2	hsa-miR-21-5p	0.041029046	3.64E-18
SNHG1	CDKN2C	hsa-miR-154-5p	0.02166065	9.52E-06
SNHG1	GBP1	hsa-miR-21-5p	0.02166065	0.014315805

SNHG1	ADGRG2	hsa-miR-21-5p	0.00064624	1.35E-05
-------	--------	---------------	------------	----------

Gene expression profiling of 506 primary KIRC tumor tissues and 71 normal adjacent tissues available from TCGA database



Differential gene expression of lncRNA, miRNA and mRNA



Construction of the KIRC ceRNA network based on starBase v2.0 database and ceRNA theory



Construction of the Cox proportional hazards regression model predicting prognosis based on the significant genes in ceRNA network



Co-expression analysis of each prognostic gene in the Cox proportional hazards regression model of ceRNA network and each survival related immune cell in the Cox proportional hazards regression model of immune cell types



Estimation of the fraction of 22 immune cell types in tumor tissues and normal adjacent tissues










Identification of immune cell types associated with prognosis




Construction of the Cox proportional hazards regression model predicting prognosis based on the significant immune cell types







a




b

PVT1 ($P < 0.001$)


c

AC005154.1 ($P < 0.001$)


d

AC015813.1 ($P < 0.001$)


e

hsa-miR-21-5p ($P < 0.001$)


f

hsa-miR-130b-3p ($P < 0.001$)


g

hsa-miR-204-5p ($P < 0.001$)


h

MXD3 ($P < 0.001$)


i

VPS13D ($P < 0.001$)


j

KCNN4 ($P < 0.001$)


a




b




c




d






e








f





a

Hazard ratio

**b****c****d****e****f**